Histogenics was acquired by Ocugen, (Nasdaq: OCGN) on September 27, 2019. Histogenics (Nasdaq: HSGX) is a leader in personalized restorative cell therapies (RCT) for active living. Our first investigational product candidate, NeoCart® is a proprietary RCT that rebuilds a patient’s own knee cartilage, treating pain at the source and potentially preventing progression to osteoarthritis (OA). Read our community guidelines: https://goo.gl/Qtusgh